Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Almotriptan · 2 trials · 1 indication
Headache pain free is defined as a decrease in baseline pain intensity from severe, moderate or mild to no pain, without the use of supplemental pain medication and/or anti-emetic medication (including a second dose of study medication) within 2 (or 24) hours of first dose of study medication. Sustained pain free is defined as pain free at 2 and 24 hours without the use of supplemental pain medication and/or anti-emetic medication (including a second dose of study medication) within 24 hours.
| Arm | Type | Description |
|---|---|---|
| Almotriptan Malate | EXPERIMENTAL | Patients will take one 12.5 mg almotriptan malate tablet by mouth after the onset of migraine headache pain |
| Name | Type | Description |
|---|---|---|
| Almotriptan Malate | DRUG | Patients will take one 12.5 mg almotriptan malate tablet by mouth after the onset of migraine headache pain |
Inclusion Criteria: * Have a history of migraine for at least one year * Have an average of 1 - 14 migraines per month for the 6 months prior to study entry * Able to swallow oral medication * Able to complete a headache diary * Only taking one migraine preventive medication and on the same dose of...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 13 | PHASE3 | Atogepant |
| Pfizer Inc. | PFE | 9 | PHASE3 | Rimegepant |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Galcanezumab |
| Amgen Inc. | AMGN | 2 | PHASE3 | Erenumab Dose 1 |
| Ki Health Partners. LLC | RVNC | 1 | - | Daxibotulinumtonix A |
Almotriptan is used for the treatment of migraine. It is a small molecule being developed by Johnson & Johnson (JNJ) for the neurology therapeutic area. The drug is currently in Phase 3 clinical development and is being studied in adolescent patients aged 12 years and older.
Almotriptan is being developed by Johnson & Johnson, which trades under the ticker JNJ. The company is conducting clinical trials to evaluate the drug for the treatment of migraine in adolescent patients.
Almotriptan is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 3 trials have been completed, with a total enrollment of 1,313 participants.
Almotriptan has been studied in two completed Phase 3 trials. NCT00210483 evaluated three dosage strengths of Almotriptan Malate (AXERT) in 866 adolescents with acute migraine. NCT00257010 assessed the long-term safety of the drug in 447 adolescents over one year.
Yes, Almotriptan is the same as AXERT. The clinical trial NCT00210483 refers to Almotriptan Malate as AXERT, indicating that AXERT is a brand name for the drug. Both names refer to the same medication used for migraine treatment.